How to Cite
Abstract
References
Моисеенко В.М., Семиглазов В.В., Тюляндин С.А. Современное лекарственное лечение местнораспространенного и метастатического рака молочной железы. С.-Пб.: Грифон. — 1997. — 254 с.
Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study // Europ. J. Cancer. — 2006. — Vol. 42. — № 101. — Р. 895-904.
Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases // Lancet. — 1896. — Vol. 1. — № 2. — P. 104-107
Berry D.A., Cirrincione C., Henderson I.C. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer // JAMA. — 2006 . — Vol. 14. — Р. 1658-1667
Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer // J. Clin. Oncol. — 1998. — Vol.19. — Р 1718-1729.
Cuzick J., Ambroisine L., Davidson N. et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials // Lancet. — 2007. — Vol. 369. — Р 1711-1723.
Davidson N.E., O’Neill A.M., Vukov A.M. et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188) // J. Clin. Oncol. — 2005. — Vol. 23. — Р 5973-5982.
Fisher B., Anderson S., Tan-Chiu E. et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 // i bid. — 2001. — Vol.19. — Р 931-942.
Forward D.P, Cheung K.L., Jackson L., Robertson J.F Clinical and endocrine data for goserelin plus anastrozole as secondline endocrine therapy for premenopausal advanced breastcancer // Br. J. Cancer. —2004. — Vol. 90.—Р 590-594.
Francis P Fleming G. and Nasi M. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the SOFT, TEXT, and PERCHE Trials // The Breast 12 (Suppl 1): A-P104, S44, 2003.
Gnant M., Mlineritsch B., Schippinger W. et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer // New Engl. J. Med.—2009. — Vol. 360.—Р 679-691.
Jakesz R., Hausmaninger H., Kubista E. et al. Randomised adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group trial 5 // J. Clin.l Oncol.—2002. — Vol. 20. — Р 4621-4627.
Hackshaw A., Baum M., Fornander T. et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer // J Natl Cancer Inst. — 2009. — Vol. 101. — Р 341-349.
Kaufmann M., Jonat W., Blameyc R. et al. On behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group. Survival analyses from the ZEBRA study: goserelin (ZoladexTM) versus CMF in premenopausal women with node-positive breast cancer // Europ. J. Cancer. — 2003. — Vol. 39. — Р 1711-1717.
Klijn J.G., Blamey R.W., Boccardo F. et al. Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomised trials // J. Clin. Oncol.—2001. — Vol. 19. — Р 343-353.
Leung S.F., Tsao S.Y, Teo P.M. et al. Ovarian ablation failures by radiation: a comparison of two dose schedules // Br. J. Radiol. — 1991. — Vol. 64. — Р 537-538.
Pagani O., O’Neil A., Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI // Europ. J. Cancer. — 1998. — Vol. 34. — Р 632-640.
Robert N.J., Wang D., Cella S. et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer [abstract] // Proc Am Soc Clin Oncol. — 2003. — Vol. 22. — A16. — Р 237.
Robert N.J., Wang M., Cella D. et al. Phase III comparison of tamoxifen vs tamoxifen with ovarian ablation in premenopausal women with axillary node negative, hormone receptor positive, breast cancer <=3 cm (INT 0142 // 39th AsCO Annual Meeting; 2003 Chicago (ILL). Available from: http://www.asco.org/portal/site/ASCO/
Roche H., Kerbrat P., Bonneterre J. et al. Complete hormonal blockade versus chemotherapy in premenopausal earlystage breast cancer patients (pts) with positive hormonereceptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 trial // Proc. Amer. Soc. Clin Oncol. — 2000. — Vol. 72a (abstract 279).
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...